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1. Introduction 
Haemostatic system has several important functions: to keep blood in a fluid state, to arrest 
bleeding at the site of vascular injury by formation of a haemostatic plug and to destroy the 
plug slowly when healing takes place. Normal physiology constitutes a delicate balance 
between procoagulant and anticoagulant properties of this system, and a deficiency or 
exaggeration of any one may lead to either haemorrhage or vascular thrombosis 
respectively. Haemostatic factors have an important role in prothrombotic state and in the 
pathogenesis of cardiovascular diseases. Vascular, platelet and coagulation factors 
contribute to the development of coronary artery disease.  
The main focus here is on the general implication of acute coronary event on coagulation 
factors, and its effect to the haemostatic system by inducing a hypercoagulable state. This 
state (or also described as prothrombotic state) is defined as a tendency or propensity to 
develop vascular thrombosis due to an abnormality in the coagulation system. 
Thrombophilia is another terminology describing the same condition. Although 
hypercoagulable state is commonly referred to venous thrombosis when coagulation system 
is involved, it is not an exclusive feature to this blood vessel. Its existence will lead to a 
harmful effect either as recurrent thrombo-embolic (TE) event or tissue damage due to 
ischaemic complications. 
APTT is a simple and widely available test commonly used to screen for hypocoagulable 
state in bleeding disorders. Whether APTT is suitable as a routine screening test for 
hypercoagulable state is currently unknown. It is important to understand the 
pathophysiology of arterial thrombosis triggered by haemostatic factors and how this 
affect the APTT results particularly during acute coronary event. In addition, clinical 
consequences of hypercoagulable state in coronary artery disease are well recognized 
and controlling this condition has been applied successfully to the patient management 
protocol. Other concern includes potential errors that can falsely lead to shortened 
APTT results which should be highlighted to improve the clinical and laboratory 
practices.  
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2. Haemostasis and laboratory investigations 
Formation of haemostatic plug is under a regulated physiological process. Haemostatic plug 
or blood clot or also known as thrombus is the end product of serial activations of the 
haemostatic system, starting from an injury or any insult usually to the blood vessel wall or 
endothelium. The basic physiology of haemostatic system includes the blood vessel, 
platelets, von Willebrand factor (vWF) and coagulation system. The coagulation system is 
controlled by inhibitors especially the natural anticoagulant proteins, namely the protein C, 
protein S, antithrombin and others. Fibrinolytic activity is essential in maintaining the 
patency of blood vessel lumen by removing the haemostatic plug during its course of 
recovery. Each of the components in the haemostatic system plays their role at the right time 
and at the right place that will ensure the haemostatic plug is formed when appropriate. 
Knowledge on the components and serial activations of the haemostatic system is important 
in order to understand the pathophysiology of either thrombotic (hypercoagulable) or 
haemorrhagic (hypocoagulable) disorders.  
There are two main types of measurements related to haemostatic disturbances in the 
investigations of the prothrombotic state in cardiovascular disease: measurement of levels of 
haemostatic factors and measurement of activation products of haemostasis. In the former 
type of measurements, the most promising factors identified have been fibrinogen, factor 
VIII (FVIII), factor VII (FVII), vWF and the fibrinolytic variables i.e tissue-type plasminogen 
activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) (Fareed et al., 1998).  
Common laboratory findings indicating the presence of hypercoagulable state from the 
haemostatic point of view include elevated coagulation factors (FVIII and others), vWF, 
fibrinogen, positive activated protein C resistance (APC-R) assay, shortened APTT (mainly 
as a result of high factor VIII and other coagulation factors) and etc. The function of protein 
C system in the anticoagulation pathway can be detected by APC-R assay. In this test, the 
function of protein C to inactivate factor VIIIa and factor Va is assessed by special 
coagulation test. In brief, the presence of high FVIII (or other factors) which is usually part 
of acute phase protein will lead to ineffective inhibition to this factor by protein C and hence 
the detection of this condition as a positive APC-R assay. There are many other factors that 
may give rise to a positive APC-R assay but in the context of coronary artery disease, it is 
partly explained by high factor VIII (see below).  
The prothrombotic or hypercoagulable state is not easily detected by routine laboratory tests 
unlike the hypocoagulable state. So far, no coagulation screening test is available to detect a 
hypercoagulable state, whether it is due to congenital or acquired thrombotic disorders, 
with the exception of lupus anticoagulant (LA). In hypocoagulable state, APTT is a useful 
screening test in the investigation of bleeding disorders. Prolonged APTT and corrected 
result after mixing test is most likely to be associated with hypocoagulable disorder due to 
coagulation factor/s deficiency. Previous finding on the association of shortened APTT and 
venous thrombosis has opened some lights to the possibility of using this routine 
coagulation test as a screening method for the risk of TE disorder. Unfortunately there is still 
no consensus to use APTT as a routine screening test in clinical practice for the investigation 
of hypercoagulable state. 
Shortened APTT could be a screening tool to be considered for hypercoagulable state during 
acute thrombotic episodes. However shortened APTT was also detected during venous TE 
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event free interval (Legnani et al., 2002; Tripodi 2004) among patients who had past history 
of vascular thrombosis. There was a report that showed the presence of shortened APTT at 
any time was related to a 10-fold increased incidence of TE events (McKenna et al., 1977). 
Further investigation including immunological and specialized coagulation tests may be 
required to find the aetiology of thrombosis in patients presenting with TE disorders.  
Shortened APTT was described in acute conditions of both venous and arterial thrombosis. 
The role of APTT as a screening tool in asymptomatic individuals or during episodes of TE 
free event is probably justified, though it may not be highly sensitive. Similar application 
goes to the screening ability of this test in hypocoagulable conditions due to its limitation in 
detecting mild coagulation factor deficiency. However, using APTT as a screening test in 
patients with positive LA (antiphospholipid syndrome) is clearly useful and had been 
established for a long time. In the presence of LA, a paradoxical finding of prolonged APTT 
is the hallmark of this condition and its presence is strongly associated with 
hypercoagulable state.  
In acute arterial thrombosis such as coronary artery thrombosis, similar finding of shortened 
APTT was also described as seen in venous thrombosis (Abdullah WZ. et al., 2010). There 
was a significant negative correlation between APTT and FVIII, which was described in the 
similar study. APTT is a robust and simple test that is available in most laboratories in all 
hospitals. However the natural limitation of APTT is the major reason preventing it as a 
powerful screening tool for both hypo and hypercoagulable states. 
Abnormally shortened APTT was reported to be associated with elevated plasma level of 
FVIII (Ten Boekal & Bartels, 2002). Elevated FVIII levels and probably other coagulation 
factors play a pathogenic role in the mechanism of abnormally shortened APTT during 
acute coronary event or related to venous thrombosis (Abdullah WZ et al., 2010; Tripodi et 
al., 2004)). Hence in arterial thrombosis, presence of high coagulation factors (particularly 
FVIII) and positive APC-R assay were found similar to the reported findings in venous 
thrombosis. Majority of the patients with positive APC-R assay also could have high 
coagulation factors, particularly FVIII.  
2.1 APTT test in clinical practice 
APTT is a routine screening test for the investigation of bleeding tendency, in both acquired 
and congenital disorders. It is also indicated pre-operatively to detect a hypocoagulable 
state that can lead to excessive bleeding during or after surgery. There are many APTT 
reagents in the market and it is the responsibility of the laboratory personnel to ensure the 
results produced from this test are accurate and precise.  
APTT test was originally performed to screen the function of coagulation system, mainly for 
the intrinsic pathway factors: factor XII, XI, IX and VIII. Various APTT reagents for different 
purposes are now available, including for screening of factor deficiencies and lupus 
anticoagulant. The normal reference ranges are expected to be different from one laboratory 
to another depending on the types of reagents and coagulometers. There are two major 
principles of clot detection for APTT test. The mechanical and optical methods, both 
measure the time to form a fibrin clot after adding the reagents to the test plasma. The time 
is commonly expressed in second (s). Plasma containing normal levels of clotting factors will 
clot within the time in normal ranges which should be established according to the reagent 
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and equipment used in the local laboratory. The reference normal range is determined by 
establishing the values using normal healthy volunteers of the local population. It is 
important for the clinical personnel to know the normal range of their local laboratory when 
interpreting the patients’ APTT results. The same principle also applies to other coagulation 
tests like prothrombin time, thrombin time, fibrinogen and etc. 
There are limitations with APTT test, for example possible pre-analytical errors that could 
occur during venepuncture procedure or during sample collection. Inappropriate blood 
taking procedure may lead to coagulation factors activation and falsely giving a shortened 
APTT results. Other problem with APTT is the consistency in reporting the results. The 
coagulation laboratory should practice an appropriate quality procedure, including 
accuracy and precision testing, participation in internal and external quality assurance 
programme, establishment of a normal reference ranges and other related requirements.  
Validation process should be done regularly whenever changes occur in the reagents 
(including lot number), equipments and etc. Laboratories running APTT and other 
haemostatic tests should follow the standard guideline for coagulation study to avoid errors 
(pre-analytical, analytical and post analytical) by practicing a regular auditing, considering 
the use of uncertainty of measurement in the results reporting (or when consulted) and 
verifying the correct normal reference ranges for local use. By doing this, the finding of 
shortened APTT can be recognized consistently in cases with high coagulation factors or 
due to other reasons that can contribute to this effect. Ability to detect the evidence of 
hypercoagulable state through this test is strictly dependent on the laboratory performance 
in their practice.  
2.2 Haemostatic investigations related to hypercoagulable state 
TE event involving venous thrombosis is the outcome of a hypercoagulable state and 
usually related to increased haemostatic factors or decreased natural anticoagulant proteins. 
Direct and indirect involvements of haemostatic system in arterial thrombosis have been 
also well recognized and hence hypercoagulable state is a pathological condition present in 
both arterial and venous thromboses (Virchow’s triad). Anti-phospholipid syndrome, APC-
R assay, deficiencies of protein C, protein S and antithrombin are the most common causes 
being investigated when patients present with venous TE disorders.  
The group of tests performed in the investigation of hypercoagulable state is also known as 
thrombophilia study. Congenital protein C, protein S, antithrombin deficiencies, factor V 
Leiden and prothrombin gene mutations are among the genetic factors associated with 
venous thrombosis included in the thrombophila study. Among specialised haemostatic 
tests in the investigation of TE disorders are protein C, protein S, antithrombin 
activity/antigen assays, APC-R assay and LA tests to detect underlying thrombophilic 
disorders. Thrombosis is the outcome of multiple contributing factors and hence the above 
mentioned factors might be compounded with other conditions such as medical diseases, 
hyperhomocysteinaemia, high levels of coagulation factors (for example secondary to oral 
contraceptive pills) and etc. 
Arterial thrombosis is associated with medical conditions such as smoking, diabetes 
mellitus, obesity, hypertension and etc. The laboratory investigation for arterial thrombosis 
is mainly related to the traditional risk factors mentioned above, for example lipid profile, 
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glucose levels, biochemical tests and etc. Some local guidelines include thrombophilia 
investigation similar to venous thrombosis for young patients presenting with ‘premature” 
arterial thrombosis (for example less than 40 years old) or recurrent arterial events. 
Currently only homocysteine measurement and antiphospholipid antibodies detection are 
clearly indicated in the investigation of arterial thrombosis (hypercoagulable risk factors) 
especially in young patients without other known risk factors. In arterial thrombosis, the 
association with other conditions (including heritable thrombophilia) is unproven and not 
sufficient to change therapy for primary or secondary prevention of the disease. 
APC-R state can be due to acquired or inherited disorders. APC-R assay is a form of 
specialised coagulation test which is done mainly for the screening of APC-R state due to 
factor V Leiden (FVL) mutation. This condition is associated with hypercoagulable state and 
has been reported to be high among Caucasians. FVL mutation is associated with venous 
thrombosis and the risk is higher in homozygous state than the heterozygous state. The 
mutated factor V molecule in FVL results in failure or ineffective inactivation by the protein 
C (protein S functions as cofactor).  
The coagulation assay to detect this FVL mutation is sensitive and was also reported to be 
specific. However similar to other coagulation studies, there are certain limitations with 
APC-R assay in which the positive results could be due to other variables (high FVIII & 
other coagulation factors or protein S deficiency). Confirmation with molecular test is 
therefore the standard method to diagnose FVL mutation. However in coronary artery 
thrombosis, its association with FVL mutation was debatable (Cushman et al., 1998). There 
is probably a weak association of this mutation with coronary artery disease particularly in 
young smoking females. The presence of high coagulation factors may lead to a positive 
APC-R assay but not due to the FVL mutation. Hence positive APC-R assay is an evidence 
of hypercoagulable state, whether it is due to FVL or related to haemostatic factors.  
Thromboelastography (TEG) is a haemostatic analyser which has been introduced in clinical 
practice many years ago, serving as a form of point of care testing. However it is not widely 
available routinely. TEG parameters reflect the function of the haemostatic components and 
able to detect both hypo and hypercoagulable states. Previous studies have shown that 
certain parameters of TEG are useful indicators for the presence of prothrombotic state such 
as, maximum amplitude (MA). One study showed that this parameter of TEG predicted 
post operative thrombotic complications including myocardial infarction (McCrath et al., 
2005).  
So far, basic coagulation tests to detect the presence of hypercoagulable state are still under-
utilised but shortened APTT and positive APC-R assay could be applied for this purpose 
although with some limitations, as described above. Unlike APTT, APC-R assay is usually 
done in a specialised coagulation laboratory and not easily available in most hospitals. 
Ideally this investigation should be interpreted by an experienced scientist or haematologist 
rendering its usefulness as a screening test for hypercoagulable state is limited.  
3. Haemostasis and coronary artery disease 
Acute coronary syndrome (ACS) is a condition described for coronary artery 
atherothrombosis which compromised the blood supply to the myocardium and followed 
by clinical and/or laboratory evidences of ischaemia. ACS comprises of unstable angina, 
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non-ST segment elevation myocardial infarction and ST segment elevation infarction. 
Association of haemostatic factors with ACS has been widely investigated and thoroughly 
discussed in the literatures (Cooper et al., 2000; Fuster et al., 2005). The insult on the 
coronary vessel is mainly from atherosclerotic process and its complication (example plaque 
rupture) leading to an acute thrombotic event from the haemostatic activation. The 
formation of blood clot (fibrin) from this activity gives a sudden blockage of the vessel 
lumen and produced the signs and symptoms of ACS mainly chest pain, 
electrocardiographic and biochemical changes. The schematic drawing of coagulation 
cascade activation and fibrinolytic activity is shown in figure 1.  
 
Fig. 1. Coagulation activation, fibrinolysis and tissue factor pathway inhibitor. (u-PA, 
urokinase plasminogen activator; t-PA, tissue plasminogen activator) 
The mechanism of thrombosis according to Virchow’s triad explained the hypercoagulable 
process. Most of the risk factors for venous thrombosis are caused by stasis or changes in 
overall total blood coagulabality, while vessel wall damage is the main cause of 
thrombogenicity in arterial thrombosis. Vascular endothelium is involved in a wide range of 
homoestatic functions including maintaining the balance of anticoagulant and procoagulant 
forces. On the anticoagulant side, the endothelium releases heparin sulfate and prostacyclin, 
expresses thrombomodulin, t-PA, tissue factor pathway inhibitor and endothelial nitric 
oxide synthase which provide a non-thrombogenic cell-surface membrane. On the 
prothrombotic side, endothelial cells release von Willebrand factor and plasminogen 
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activator inhibitor type-1, expose critical binding sites for coagulation factor complexes and 
some other functions. The endothelium is capable of integrating multiple feedbacks and 
capable of shifting the haemostatic balance from time to time that allows the haemostatic 
system with tremendous flexibility (Rosenberg and Aird, 1999). However the endothelium is 
also vulnerable to focal dysfunction resulting in many ways including narrowing of the 
lumen and increased risk of sudden obstruction as seen in the various phases of 
atherothrombosis.  
Although Protein C, protein S and antithrombin do not confer an increased risk of arterial 
thrombosis, other anticoagulant mechanisms must be responsible for maintaining the patent 
of vascular lumen, particularly in coronary vessels. Fibrinolytic enzymes play a critical role 
to keep the lumen patent by preventing fibrin deposition within the vascular bed of the 
heart. These enzymes are t-PA and urokinase-type plasminogen activator. Binding of t-PA 
to fibrin enhances the conversion of thrombus-bound plasminogen into plasmin. Plasmin is 
capable to digest the fibrinogen, fibrin and factor VIII. The anticoagulant property of tissue 
factor pathway inhibitor helps to control the procoagulant activity of the extrinsic 
coagulation factors (FVIIa and tissue factor). Similarly APC stimulates fibrinolysis by 
destroying plasma inhibitors of t-PA. Haemostatic balance within the coronary vessels is 
controlled by a vascular bed-specific circuit or feedback system. Hence there is a strong 
possibility that thrombosis in coronary artery arises through the interplay of plaque rupture 
and an alteration of local haemostatic circuit (Rosenberg and Aird, 1999). 
In addition to the consequences of atherosclerotic plaque rupture where the thrombus 
formed in the coronary artery, the systemic effect of this acute event is seen almost 
immediately. In one study, shortened APTT was significantly different in ACS patients 
compared to stable coronary artery disease patients (SCAD) when they presented early to 
the hospital (Abdullah WZ., et al 2010). High FVIII levels were also found to be significant in 
ACS patients compared to the SCAD group. None of the SCAD patients had shortened 
APTT result in their study although some of them were having elevated FVIII levels (which 
did not affect the APTT results). Significantly high vWF and fibrinogen were seen among 
ACS patients compared to the SCAD patients and most patients with APCR state also had 
high FVIII levels. (Abdullah WZ., et al 2011). Interestingly, inversed relationship between 
FVIII and APTT was shown among coronary heart disease patients indicating that 
shortened APTT is partly explained by increased FVIII levels (Figure 2 and table 1). 
Haemostatic system involves in the initiation of ACS through haemostatic activation 
(platelet and coagulation system activation) and hypercoagulable state is a finding following 
this event, as evidenced by high vWF, fibrinogen and FVIII levels. The net outcome of the 
effect of these hypercoagulable factors is detected as shortened APTT as shown by the above 
study. 
Patients with arterial thrombosis also have a form of hypercoagulable state, manifested by 
higher baseline concentrations of fibrinogen and elevated factor VII activity. Increased 
fibrinogen concentration is a strong and independent predictor of cardiovascular risk in 
apparently healthy person as well as in person manifested as coronary heart disease 
(Thomas and Roberts, 1997). Clinical studies have shown that subjects with higher plasma 
levels of procoagulant proteins (including vWF and coagulation factors) had an increased 
risk of myocardial infarction (Rosenberg and Aird, 1999).  
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The role of platelet and vWF in arterial thrombosis is not elaborated in details here. 
Obviously there is an integrated process from various haemostatic components that 
eventually promote a hypercoagulable state throughout the entire process. Furthermore 
shortened APTT does not account for the platelet reactivity in atherothrombosis. The 
contribution of haemostatic system in the development of atherothrombosis has been 
greatly discussed in literatures. It is also interesting that this system may also determine the 
outcomes of the disease. The beneficial effects from anti-platelet, anticoagulation and anti-
thrombotic therapies in prevention and treatment of ACS proved that hypercoagulable state 
should be controlled to avoid its harmful effects in coronary artery disease. 
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Fig. 2. The correlation between FVIII and APTT among coronary heart disease patients. 
 
Variable (S.E) (95% CI) p value* 
FVIII -0.013(0.003) (-0.019,-0.007) < 0.0001 
(R square = 0.097 (10%), predictor = FVIII, dependent variable = APTT. *p value is significant when ≤ 0.05) 
Table 1. The correlation between FVIII level and APTT among coronary heart disease 
patients.  
4. Consequences of hypercoagulable state following ACS 
The after effect of acute coronary thrombosis may further complicate both the local coronary 
artery and systemic circulation by the burden of this hypercoagulable state. This condition 
can be harmful and leads to an imbalance state between the natural anticoagulant and 
procoagulant activities. Hypercoagulable state potentially caused repeated episodes of 
vascular thrombosis and may lead to increased in morbidity and mortality. This is especially 
true if this state is not controlled adequately with the given treatment, especially the 
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anticoagulant and antiplatelet therapy. Resistance to certain anti-platelet drugs have been 
reported and extensively discussed in the literatures, which partly explained why some 
patients developed repeated thrombotic event despite on adequate therapy (Flaherty MP., et 
al 2011).  
5. Conclusion 
ACS by definition is a hypercoagulable state and shortened APTT is a useful haemostatic 
marker. Shortened APTT is associated with increased coagulation factors for example 
fibrinogen and FVIII. Previous studies have shown a consistent association of increased 
haemostatic factors in acute coronary artery thrombosis. It is now understood that 
hypercoagulable state is likely to be present before or after this event. Limited investigation 
is recommended pertaining to haemostatic tests in coronary artery thrombosis.  
Haemostatic activities for example thrombin generation, platelet activation and abnormal 
fibrinolysis may significantly influence the outcomes of patients with this disease. In 
patients with risk factors of coronary artery disease, the presence of shortened APTT at the 
onset of acute clinical presentation is associated with higher chance of ACS. There is a 
relationship of shortened APTT and hypercoagulable state during acute thrombotic 
episodes, although the possibility remains that an acute phase responses (increase 
fibrinogen and FVIII) present at a wide range of time since the initial onset of vascular injury 
during the atherosclerotic process. 
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